Efficacy, Safety, and Determination of RP2D of ABBV-383, a BCMA Bispecific Antibody, in Patients with Relapsed/refractory Multiple Myeloma (RRMM).
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined